Study protocol for a randomised pragmatic trial comparing the clinical and cost effectiveness of Lithium and Quetiapine augmentation in treatment resistant Depression (the LQD study) by Marwood, L, Taylor, R, Goldsmith, K, Romeo, R, Holland, R, Pickles, A, Hutchinson, J, Dietch, D, Cipriani, A, Nair, R, Attenburrow, M-J, Young, AH, Geddes, JR, McAllister-Williams, RH, Cleare, AJ

“…Lithium and the atypical antipsychotic quetiapine are two such add-on therapies and are currently recommended as first line options for treatment resistant depression. …”

Comparative efficacy and acceptability of antimanic drugs in acute mania: A multiple-treatments meta-analysis by Cipriani, A, Barbui, C, Salanti, G, Rendell, J, Brown, R, Stockton, S, Purgato, M, Spineli, L, Goodwin, G, Geddes, J

“…Olanzapine, risperidone, and quetiapine led to significantly fewer discontinuations than did lithium, lamotrigine, placebo, topiramate, and gabapentin. …”

Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. by Cipriani, A, Barbui, C, Salanti, G, Rendell, J, Brown, R, Stockton, S, Purgato, M, Spineli, L, Goodwin, G, Geddes, J

“…Olanzapine, risperidone, and quetiapine led to significantly fewer discontinuations than did lithium, lamotrigine, placebo, topiramate, and gabapentin. …”

Clinical and regulatory implications of active run-in phases in long-term studies for bipolar disorder by Cipriani, A, Barbui, C, Rendell, J, Geddes, J

“…Results: Six placebo-controlled trials comparing aripiprazole, olanzapine, quetiapine and ziprasidone were found in the FDA website. …”

Clinical and regulatory implications of active run-in phases in long-term studies for bipolar disorder. by Cipriani, A, Barbui, C, Rendell, J, Geddes, J

“…RESULTS: Six placebo-controlled trials comparing aripiprazole, olanzapine, quetiapine and ziprasidone were found in the FDA website. …”

Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia by Barber, S, Olotu, U, Corsi, M, Cipriani, A

“…Clozapine plus amisulpride versus clozapine plus quetiapine One study showed a significant benefit of amisulpride over quetiapine in the short term, for both change in global state (Clinical Global Impression (CGI): 1 RCT, n = 50, MD -0.90, 95% CI -1.38 to -0.42, very low quality evidence) and mental state (Brief Psychiatric Rating Scale (BPRS): 1 RCT, n = 50, MD -4.00, 95% CI -5.86 to -2.14, low quality evidence). …”

Lithium for acute mania by McKnight, R, De La Motte De Broöns De Vauvert, S, Chesney, E, Amit, B, Geddes, J, Cipriani, A

“…Limited evidence suggests little or no difference between lithium and other mood stabilisers (valproate, carbamazepine) or antipsychotics (risperidone, quetiapine, haloperidol). Olanzapine may be an exception, as it is probably slightly more effective than lithium. …”

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis by Leucht, S, Örey, D, Richter, F, Samara, M, Kissling, W, Stapf, M, Lässig, B, Cipriani, A, Barbui, C, Spineli, L, Mavridis, D, Salanti, G, Engel, R, Geddes, J, Davis, J

“…The standardised mean differences with 95% credible intervals were: clozapine 0.88, 0.73-1.03; amisulpride 0.66, 0.53-0.78; olanzapine 0.59, 0.53-0.65; risperidone 0.56, 0.50-0.63; paliperidone 0.50, 0.39-0.60; zotepine 0.49, 0.31-0.66; haloperidol 0.45, 0.39-0.51; quetiapine 0.44, 0.35-0.52; aripiprazole 0.43, 0.34-0.52; sertindole 0.39, 0.26-0.52; ziprasidone 0.39, 0.30-0.49; chlorpromazine 0.38, 0.23-0.54; asenapine 0.38, 0.25-0.51; lurasidone 0.33, 0.21-0.45; and iloperidone 0.33, 0.22-0.43. …”

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. by Leucht, S, Cipriani, A, Spineli, L, Mavridis, D, Orey, D, Richter, F, Samara, M, Barbui, C, Engel, R, Geddes, J, Kissling, W, Stapf, M, Lässig, B, Salanti, G, Davis, J

“…The standardised mean differences with 95% credible intervals were: clozapine 0·88, 0·73-1·03; amisulpride 0·66, 0·53-0·78; olanzapine 0·59, 0·53-0·65; risperidone 0·56, 0·50-0·63; paliperidone 0·50, 0·39-0·60; zotepine 0·49, 0·31-0·66; haloperidol 0·45, 0·39-0·51; quetiapine 0·44, 0·35-0·52; aripiprazole 0·43, 0·34-0·52; sertindole 0·39, 0·26-0·52; ziprasidone 0·39, 0·30-0·49; chlorpromazine 0·38, 0·23-0·54; asenapine 0·38, 0·25-0·51; lurasidone 0·33, 0·21-0·45; and iloperidone 0·33, 0·22-0·43. …”

Duloxetine versus other anti-depressive agents for depression. by Cipriani, A, Koesters, M, Furukawa, T, Nosè, M, Purgato, M, Omori, I, Trespidi, C, Barbui, C

“…We found 11 studies (overall 3304 participants) comparing duloxetine with one selective serotonin reuptake inhibitor (SSRI) (six studies versus paroxetine, three studies versus escitalopram and two versus fluoxetine), four studies (overall 1978 participants) comparing duloxetine with a newer antidepressants (three with venlafaxine and one with desvenlafaxine, respectively) and one study (overall 453 participants) comparing duloxetine with an antipsychotic drug which is also used as an antidepressive agent, quetiapine. No studies were found comparing duloxetine with tricyclic antidepressants. …”